The latest price target for Protagonist Therapeutics (NASDAQ:PTGX) was reported by HC Wainwright & Co. on September 12, 2024. The analyst firm set a price target for $50.00 expecting PTGX to rise to within 12 months (a possible 7.00% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Protagonist Therapeutics (NASDAQ:PTGX) was provided by HC Wainwright & Co., and Protagonist Therapeutics maintained their buy rating.

The last upgrade for Protagonist Therapeutics Inc happened on October 12, 2021 when JP Morgan raised their price target to $55. JP Morgan previously had a neutral for Protagonist Therapeutics Inc.

There is no last downgrade for Protagonist Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protagonist Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protagonist Therapeutics was filed on September 12, 2024 so you should expect the next rating to be made available sometime around September 12, 2025.

While ratings are subjective and will change, the latest Protagonist Therapeutics (PTGX) rating was a maintained with a price target of $40.00 to $50.00. The current price Protagonist Therapeutics (PTGX) is trading at is $46.73, which is within the analyst’s predicted range.